
The Library
Browse by Warwick Author
![]() | Up a level |
Number of items: 8.
2020
Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B. et al.
(2020)
Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT.
Health Technology Assessment, 24
(40).
pp. 1-190.
doi:10.3310/hta24400
2019
Drayson, Mark T., Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T., Whittaker, Anna C., Hawkey, Peter, Low, Eric and Dunn, Janet A. (2019) Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62). pp. 1-94. doi:10.3310/hta23620
Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen B., Dawkins, Bryony et al.
(2019)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM) : a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
The Lancet. Oncology, 20
(12).
pp. 1760-1772.
doi:10.1016/S1470-2045(19)30506-6
Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel et al.
(2019)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
The Lancet, 393
(10191).
pp. 2599-2612.
doi:10.1016/S0140-6736(19)30650-6
2018
Chicca, I. J., Heaney, J. L. J., Iqbal, Gulnaz, Bowcock, S., Planche, T., Wood, J., Raynes, K., Hawkey, P., Pratt, G., Yong, K., Dunn, Janet A. and Drayson, M. T. (2018) Major changes in levels of regulatory cytokines and functional antibodies contribute to severe immunodeficiency of myeloma patients and persist at one year post diagnosis. Haematologica, 103 (Supplement 1). pp. 1-48. P02.
Bowcock, S., Atkin, C., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M. and Co-Investigators, Teamm (2018) Does a long diagnostic pathway in myeloma lead to more advanced disease at presentation? An analysis from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-PO-098 [pp 99]. doi:10.1111/bjh.15226
Bowcock, S., Planche, T., Iqbal, Gulnaz, Pratt, G., Yong, K., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M. and Co-Investigators, Teamm (2018) Levofloxacin prophylaxis in newly diagnosed myeloma reduces febrile episodes and death without increasing healthcare associated infections : results from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-OR-012 [pp16]. doi:10.1111/bjh.15226
Atkin, C., Drayson, M., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Higgins, Helen B., Dunn, Janet A. and Bowcock, S. (2018) Presenting symptoms of patients with multiple myeloma : data from the TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial. British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-PO-094 [pp 96]. doi:10.1111/bjh.15226
This list was generated on Fri May 20 11:32:09 2022 BST.